Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30054858 | 1.00 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL6347068 | 1.00 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL30421873 | 1.00 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL33377974 | 1.00 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL2568254 | 1.00 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL762530 | 1.00 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL2384012 | 0.97 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL800127 | 0.97 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL6383724 | 0.97 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB | |
| SCHEMBL119535 | 0.97 | KMT2A (0.50) | KMT2AEPHX2FABP5FABP7CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099937-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-12 | — | — | US | disclosed |
| US-20180099937-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099937-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | SMYD2, SETD2, SMYD3 | KMT2A 31/4885EPHX2 3767/4885FABP5 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.